Literature DB >> 20713823

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

Shanu Kohli Kurd1, Andrea B Troxel, Paul Crits-Christoph, Joel M Gelfand.   

Abstract

OBJECTIVE: To determine the incidence of depression, anxiety, and suicidality in patients with psoriasis compared with the general population.
DESIGN: A population-based cohort study using data collected as part of patient's electronic medical record from 1987 to 2002.
SETTING: General Practice Research Database. PATIENTS: Analyses included 146 042 patients with mild psoriasis, 3956 patients with severe psoriasis, and 766 950 patients without psoriasis. Five controls without psoriasis were selected from the same practices and similar cohort entry dates as patients with psoriasis. MAIN OUTCOME MEASURE: Clinical diagnoses of depression, anxiety, and suicidality among patients.
RESULTS: The adjusted hazard ratios (HRs) for receiving a diagnosis of depression, anxiety, and suicidality in patients with psoriasis compared with controls were 1.39 (95% confidence interval [CI], 1.37-1.41), 1.31 (95% CI, 1.29-1.34), and 1.44 (95% CI, 1.32-1.57), respectively. The adjusted HR of depression was higher in severe (HR, 1.72; 95% CI, 1.57-1.88) compared with mild psoriasis (HR, 1.38; 95% CI, 1.35-1.40). Younger patients with psoriasis had elevated HRs of outcomes compared with older patients with psoriasis.
CONCLUSIONS: Patients with psoriasis have an increased risk of depression, anxiety, and suicidality. We estimate that in the United Kingdom, in excess of 10 400 diagnoses of depression, 7100 diagnoses of anxiety, and 350 diagnoses of suicidality are attributable to psoriasis annually. It is important for clinicians to evaluate patients with psoriasis for these conditions to improve outcomes. Future investigation should determine the mechanisms by which psoriasis is associated with psychiatric outcomes as well as approaches for prevention.

Entities:  

Mesh:

Year:  2010        PMID: 20713823      PMCID: PMC2928071          DOI: 10.1001/archdermatol.2010.186

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  26 in total

1.  Validity of the general practice research database.

Authors:  Susan S Jick; James A Kaye; Catherine Vasilakis-Scaramozza; Luis A Garcia Rodríguez; Ana Ruigómez; Christoph R Meier; Raymond G Schlienger; Corri Black; Hershel Jick
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

2.  The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.

Authors:  H Devrimci-Ozguven; T N Kundakci; H Kumbasar; A Boyvat
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-07       Impact factor: 6.166

3.  Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.

Authors:  Daniel Mines; Deanna Hill; Holly Yu; Laura Novelli
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-06       Impact factor: 2.890

4.  Determinants of quality of life in patients with psoriasis: a study from the US population.

Authors:  Joel M Gelfand; Steven R Feldman; Robert S Stern; John Thomas; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

5.  The risk of lymphoma in patients with psoriasis.

Authors:  Joel M Gelfand; Daniel B Shin; Andrea L Neimann; Xingmei Wang; David J Margolis; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

6.  Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria.

Authors:  M A Gupta; A K Gupta; N J Schork; C N Ellis
Journal:  Psychosom Med       Date:  1994 Jan-Feb       Impact factor: 4.312

7.  An Italian study on psoriasis and depression.

Authors:  Maria Esposito; Rosita Saraceno; Alessandro Giunta; Mara Maccarone; Sergio Chimenti
Journal:  Dermatology       Date:  2006       Impact factor: 5.366

8.  Pathological worry in depressed and anxious patients.

Authors:  Iwona Chelminski; Mark Zimmerman
Journal:  J Anxiety Disord       Date:  2003

9.  Suicidal ideation in psoriasis.

Authors:  M A Gupta; N J Schork; A K Gupta; S Kirkby; C N Ellis
Journal:  Int J Dermatol       Date:  1993-03       Impact factor: 2.736

10.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Authors:  Shanu Kohli Kurd; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

View more
  150 in total

Review 1.  Th17 cells in depression.

Authors:  Eléonore Beurel; Jeffrey A Lowell
Journal:  Brain Behav Immun       Date:  2017-08-03       Impact factor: 7.217

2.  Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.

Authors:  Charlie Schmidt
Journal:  Nat Biotechnol       Date:  2015-09       Impact factor: 54.908

Review 3.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

Review 4.  Progress to Date in Advancing Stratified Medicine in Psoriasis.

Authors:  Claire Reid; Lis Cordingley; Richard B Warren; Christopher E M Griffiths
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 5.  Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.

Authors:  Attia Attia; Abdelrahman Ibrahim Abushouk; Hussien Ahmed; Mohamed Gadelkarim; Ahmed Elgebaly; Zeinab Hassan; Mohamed M Abdel-Daim; Ahmed Negida
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

Review 6.  The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities.

Authors:  Ryan Rivera-Oyola; Roselyn Stanger; Graham H Litchman; Quinn Thibodeaux; John Koo; Richard Fried; Gary Goldenberg; George Han; Sylvia Hsu; Leon Kircik; Melissa Knuckles; Andrea Murina; Jeffrey Weinberg; Jashin J Wu; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

7.  Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing.

Authors:  Harshit Nanda; Nirmaladevi Ponnusamy; Rajasree Odumpatta; Jeyaraman Jeyakanthan; Arumugam Mohanapriya
Journal:  3 Biotech       Date:  2020-01-10       Impact factor: 2.406

Review 8.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.

Authors:  Emmilia A Dowlatshahi; Marlies Wakkee; Lidia R Arends; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

9.  Impact of depressive symptoms on oxidative stress in patients with psoriasis.

Authors:  Fatih Karababa; Yavuz Yesilova; Enver Turan; Salih Selek; Hacer Altun; Sahabettin Selek
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

10.  Assessment of the Therapeutic Aspect of Systemic Non-Biologic Anti-Psoriatic Treatment Modalities Used in Combination with Methotrexate.

Authors:  Kamran Balighi; Ghodsi Seyedeh Zahra; Goodarzi Azadeh; Hejazi Pardis; Sepehri Ehsan; Azizpour Arghavan
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.